Press Release: BatuBiologics : Batu Biologics Utilizes CRISPR/cas9 Gene Editing to Modify T Cells

SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, an immuno-oncology company, has recently filed intellectual property and initiated discovery research on a new method of augmenting an anti-tumor immune response through ex vivo manipulation of the patient's T cells. The inhibition of popular "immune checkpoints" has proven to be an effective way to potentiate T cell responses as a treatment for multiple solid tumor indications. Blocking these immune checkpoints in vivo has shown significant effective